nach oben

Current Cardiology Reports

Erschienen in:

01.08.2014 | Congestive Heart Failure (J Lindenfeld, Section Editor)

Cardiac Sarcoidosis

verfasst von: Matthew M. Zipse, William H. Sauer

Erschienen in: Current Cardiology Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Cardiac sarcoidosis (CS) is a rare and under-recognized clinical entity that requires a high level of suspicion and low threshold for screening in order to make the diagnosis. CS may manifest in a variety of ways, and its initial presentation can range from asymptomatic electrocardiographic abnormalities to overt heart failure to sudden cardiac death. The aim of this literature review is to provide a comprehensive overview of CS, with an emphasis on clinical manifestations and special diagnostic and management considerations, while highlighting recent studies that have provided new insights into this unique disease.

Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong DLT, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine. 2004;83:315–34.PubMedCrossRef

Kim JS, Judson MA, Donnino R, Gold M, Cooper LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9–21.PubMedCrossRef

Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivistö SM, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270:461–8.PubMedCrossRef

Yazaki Y, Isobe M, Hiroe M, Morimoto S-I, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol Elsevier. 2001;88:1006–10.CrossRef

Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–41.PubMedCrossRef

Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–34.PubMedCrossRef

Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us? Clin Chest Med. 1997;18:681–94.PubMedCrossRef

Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130:29–32.PubMed

Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–11.PubMedCrossRef

10.

Tachibana T, Iwai K, Takemura T. Study on cause of death in the patients with sarcoidosis in Japan. Sarcoidosis Sigilim SRL. 1992;9:307–7.

11.

Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455–69.PubMedCrossRef

12.

Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–30.PubMed

13.

Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by propionibacterium acnes. BioMed Res Int. 2013;2013:1–18.CrossRef

14.

Tchernev G, Ananiev J, Cardoso JC, Wollina U, Verma SB, Patterson JW, et al. Sarcoidosis and molecular mimicry—important etiopathogenetic aspects: current state and future directions. Wien Klin Wochenschr Springer. 2012;124:227–38.CrossRef

15.

Baughman RP, Lower EE, Bois du RM. Sarcoidosis. Lancet. 2003;361:1111–8.PubMedCrossRef

16.

Schürmann M, Lympany PA, Reichel P, Müller-Myhsok B, Wurm K, Schlaak M, et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med. 2000;162:861–4.PubMed

17.

Doughan AR. Cardiac sarcoidosis. Heart. 2006;92:282–8.PubMedCentralPubMedCrossRef

18.

Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108.PubMedCrossRef

19.

Navaneethan SD, Venkatesh S, Shrivastava R, Mehta J, Israel R. Recurrent pleural and pericardial effusions due to sarcoidosis. PLoS Med. 2005;2:e63.PubMedCentralPubMedCrossRef

20.

Sekhri V, Sanal S, DeLorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;4:546–54.CrossRef

21.

Schuller JL, Lowery CM, Zipse M, Aleong RG, Varosy PD, Weinberger HD, et al. Diagnostic utility of signal-averaged electrocardiography for detection of cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:70–6.PubMedCrossRef

22.•

Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace. 2013;15:347–54. A multicenter retrospective review which represents the largest published cohort of cardiac sarcoidosis patients with ICDs.PubMedCrossRef

23.•

Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925–9. One of three 2012 studies of CS patients with ICDs. No primary prevention patients with normal LV and RV function received an appropriate therapy for VT.PubMedCrossRef

24.

Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong DLT, et al. Cardiac sarcoidosis. Medicine. 2004;83:315–34.PubMedCrossRef

25.

Schuller JL, Olson MD, Zipse MM, Schneider PM, Aleong RG, Wienberger HD, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol. 2011;22:1243–8.PubMedCrossRef

26.

Yoshida Y, Morimoto S, Hiramitsu S, Tsuboi N, Hirayama H, Itoh T. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J. 1997;134:382–6.PubMedCrossRef

27.

Gozo EG, Cosnow I, Cohen HC, Okun L. The heart in sarcoidosis. Chest Am Coll Chest Phys. 1971;60:379–88.

28.

Abeler V. Sarcoidosis of the cardiac conducting system. Am Heart J. 1979;97:701–7.PubMedCrossRef

29.

Ton K, Schulman S, Lima J, Tandri H. Cardiac Sarcoidosis Presenting as Sick Sinus Syndrome and Recurrent Ventricular Tachycardia. HRS 2014. 2014. pp. 1–1.

30.

Zipse MM, Schuller JL, Katz DF, Steckman DA, Gonzalez JE, Sung RK, et al. Atrial Arrhythmias are Common and Arise from Diverse Mechanisms in Patients with Cardiac Sarcoidosis. Heart Rhythm 2013. 2013. pp. 1–2.

31.•

Viles-Gonzalez JF, Pastori L, Fischer A, Wisnivesky JP, Goldman MG, Mehta D. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest. 2013;143:1085–90. The first retrospective study of atrial arrhythmias in CS.PubMedCrossRef

32.

Cain MA, Metzl MD, Patel AR, Addetia K. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014;113(9):1556–60.PubMedCrossRef

33.

Winters SL, Cohen M, Greenberg S, Stein B, Curwin J, Pe E, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. JAC. 1991;18:937–43.CrossRef

34.

Koplan BA, Soejima K, Baughman K, Epstein LM, Stevenson WG. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. HRTHM. 2006;3:924–9.

35.

Jefic D, Joel B, Good E, Morady F, Rosman H, Knight B, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009;6:189–95.PubMedCrossRef

36.

Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. HRTHM. 2007;4:1292–9.

37.

Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004;27:217–22.PubMedCrossRef

38.

Fleming HA, Bailey SM. Sarcoid heart disease. J R Coll Physicians Lond. 1981;15:245.PubMed

39.

Uusimaa P, Ylitalo K, Anttonen O, Kerola T, Virtanen V, Pääkkö E, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace. 2008;10:760–6.PubMedCrossRef

40.

Stees CS, Khoo MSC, Lowery CM, Sauer WH. Ventricular tachycardia storm successfully treated with immunosuppression and catheter ablation in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2011;22:210–3.PubMed

41.

Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Monogr Eur Respir Soc. 2005;32:130.

42.

Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20:578–83. Wiley Online Library.PubMedCrossRef

43.

Hamzeh NY. Management of cardiac sarcoidosis in the United States. Chest. 2012;141:154.PubMedCentralPubMedCrossRef

44.

Youssef G, Beanlands RSB, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97:2078–87.PubMedCrossRef

45.

Yeboah J, Lee C, Sharma OP. Cardiac sarcoidosis. Curr Opin Pulm Med. 2011;17:308–15.PubMedCrossRef

46.

Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis. Curr Opin Cardiol. 2012;27:181–9.PubMedCrossRef

47.

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999. pp. 736–55.

48.

Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86.PubMed

49.

Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis. 2008;51:58–73.PubMedCrossRef

50.•

Nery PB, Beanlands RS, Nair GM, Green M, Yang J, Mc Ardle BA, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014. doi:10.1111/jce.12401. This study reports a high incidence of cardiac sarcoidosis in young patients with initially-unexplained AV block.PubMed

51.

Nery PB, Mc Ardle BA, Redpath CJ, Leung E, Lemery R, Dekemp R, et al. Prevalence of Cardiac Sarcoidosis in Patients Presenting with Monomorphic Ventricular Tachycardia. Pacing and Clinical Electrophysiology. 2013.:n/a–n/a.

52.

Ward EV, Nazari J, Edelman RR. Coronary artery vasculitis as a presentation of cardiac sarcoidosis. Circulation. 2012;125:e344–6.PubMedCrossRef

53.

Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythmia Electrophysiol. 2011;4:303–9.CrossRef

54.

Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2012;18:733–46.CrossRef

55.

Chia P-L, Subbiah RN, Kuchar D, Walker B. Cardiac sarcoidosis masquerading as arrhythmogenic right ventricular cardiomyopathy. Heart Lung Circ. 2012;21:42–5.PubMedCrossRef

56.

Vasaiwala SC, Finn C, Delpriore J, Leya F, Gagermeier J, Akar JG, et al. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2009;20:473–6.PubMedCrossRef

57.

Mohsen A, Panday M, Wetherold S, Jimenez A. Cardiac sarcoidosis mimicking arrhythmogenic right ventricular dysplasia with high defibrillation threshold requiring subcutaneous shocking coil implantation. Heart Lung Circ. 2012;21:46–9.PubMedCrossRef

58.

Aggeli C, Felekos I, Tousoulis D, Gialafos E, Rapti A, Stefanadis C. Myocardial mechanics for the early detection of cardiac sarcoidosis. Int J Cardiol Elsevier Irel Ltd. 2013;168:4820–1.

59.

Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest. 1994;106:1021–4.PubMedCrossRef

60.

Adamson P, Melton I, O'Donnell J, MacDonald S, Crozier I. Cardiac sarcoidosis: the Christchurch experience. Int Med J. 2014;44:70–6.CrossRef

61.

Judson MA, Thompson BW, Rabin DL, Steimel J, Knattereud GL, Lackland DT, et al. The diagnostic pathway to sarcoidosis. Chest. 2003;123:406–12.PubMedCrossRef

62.

Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J Elsevier. 2005;150:459–63.CrossRef

63.

Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138:299–302.PubMedCrossRef

64.•

Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol. 2013;29(1015):e1–3. Describes the by which electroanatomical mapping can guide endomyocardial biopsy to improve diagnostic yield.

65.

Pieroni M, Russo Dello A, Marzo F, Pelargonio G, Casella M, Bellocci F, et al. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy. JAC Am Coll Cardiol Found. 2009;53:681–9.CrossRef

66.

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36.PubMedCrossRef

67.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging Springer. 2008;35:933–41.CrossRef

68.

Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122:1895–901.PubMedCrossRef

69.

Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther. 1996;10:495–510.PubMedCrossRef

70.

Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JCMG Elsevier Inc. 2013;6:501–11.

71.

Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:234–5.PubMed

72.

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.PubMedCrossRef

73.

Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J. 2007;29:418–22.PubMedCrossRef

74.

Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythmia Electrophysiol. 2011;4:43–8.CrossRef

75.

Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–82.PubMedCrossRef

76.

Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:133–7.PubMed

77.

Baughman RP, Costabel U, du RM B. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533–48. x–x.PubMedCrossRef

78.

Baughman RP, Drent M, Kavuru M, JUDSON MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.PubMed

79.

Mantini N, Williams Jr B, Stewart J, Rubinsztain L, Kacharava A. Cardiac sarcoid: a clinician’s review on how to approach the patient with cardiac sarcoid. Clin Cardiol. 2012;35:410–5.PubMedCrossRef

80.

Chiu C-Z, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143–6.PubMedCrossRef

81.

Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:140–7.PubMedCrossRef

82.

Yodogawa K, Seino Y, Shiomura R, Takahashi K, Tsuboi I, Uetake S, et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol. 2013;62:320–5.PubMedCrossRef

83.

Sadek MM, Yung D, Birnie DH, BEANLANDS RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034–41.PubMedCrossRef

84.

Kato Y, Morimoto S-I, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133–7.PubMed

85.

Mohsen A, Jimenez A, Hood RE, Dickfeld T, Saliaris A, Shorofsky S, et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2013.

86.

Zipse MM, Sauer WH. Electrophysiologic manifestations of cardiac sarcoidosis. Curr Opin Pulm Med. 2013;19:485–92.PubMedCrossRef

87.

Writing Committee Members, Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American college of cardiology/american heart association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American association for thoracic surgery and society of thoracic surgeons. Circulation. 2008;117:2820–40.CrossRef

88.

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRef

89.

Oni AA, Hershberger RE, Norman DJ, Ray J, Hovaguimian H, Cobanoglu AM, et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant. 1992;11:367–9.PubMed

90.

Yager JEE, Hernandez AF, Steenbergen C, Persing B, Russell SD, Milano C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant. 2005;24:1988–90.PubMedCrossRef

91.

Milman N, Andersen CB, Mortensen SA, Sander K. Cardiac sarcoidosis and heart transplantation: a report of four consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:51–9.PubMed

92.

Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transpl Elsevier. 2007;26:714–7.CrossRef

Titel: Cardiac Sarcoidosis
verfasst von: Matthew M. Zipse
William H. Sauer
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 8/2014
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-014-0514-3

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Arrhythmias in Structural Heart Disease

Catheter Ablation Guided by Real-Time MRI

Rotors as Drivers of Atrial Fibrillation and Targets for Ablation

Ischemic and Functional Mitral Regurgitation in Heart Failure: Natural History and Treatment